

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. DLP Marquette General Hospital, LLC d/b/a UP Health System - Marquette 2. 850 W. Baraga Ave. Marquette, MI 49855		In accordance with letter dated April 25, 2025,	4. Expiration Date: October 31, 2039
		3. License No.: 21-05432-04 is amended in its entirety to read as follows:	5. Docket No.: 030-18133 Reference No.:
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 9 curies total	C. For any use permitted by 10 CFR 35.300.
D. Yttrium-90 permitted by 10 CFR 35.1000	D. Microspheres (Sirtex Medical Pty Ltd, Model Sirtex Medical SIR-Spheres microspheres)	D. Not to exceed 405 millicuries per vial; 1.08 curies total	D. For use in permanent manual brachytherapy using Sirtex Wilmington, LLC, Model SIR-Spheres Yttrium-90 microspheres and delivery system permitted by 10 CFR 35.1000.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-05432-04

Amendment No. 91

Docket or Reference No.:
030-18133**CONDITIONS**

10. Licensed material shall be used or stored at the licensee's facilities located at 850 W. Baraga Ave., Marquette, Michigan, 49855.

11. The Radiation Safety Officer (RSO) for this license is William Pyle, CNMT.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User

James R. Baer, MD

John Phillip Cox, DO

Gary M. Friesen, MD

Nelson E. Gencheff, DO

Jacob M. Hakkola, MD

Christopher J. Mehall, MD

John Michael Pap, MD

Steve Pavlock, MD

Eric Schaff, MD

Material and Use

10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.200

10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300; 10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300; 10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.300 (limited to the parenteral administration of unsealed byproduct material)


**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-05432-04

Amendment No. 91

Docket or Reference No.:
030-18133

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit in 10 CFR 30.35(d) for which decommissioning financial assurance is required.
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material in the form of unsealed material and foil or plated sources to quantities below the limits specified in 10 CFR 30.72, which require consideration of the need for an emergency plan for responding to a release of licensed material.
15. In accordance with the application dated May 24, 2024, and letter dated October 4, 2024 the licensee may make changes to its radiation safety program, as it relates to the use of yttrium-90 microspheres as permitted by 10 CFR 35.1000.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**


License No.: 21-05432-04

Amendment No. 91

Docket or Reference No.:
030-18133

16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26 and applicable guidance updates for 10 CFR 35.1000 uses. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Application dated May 24, 2024 (ML24149A051)
- B. Letter dated October 4, 2024 (ML24292A043)



FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date: July 1, 2025By: _____
Bryan A. Parker
Region III